Navigation Links
New possibilities for flu antiviral and vaccine research emerge from 'Spanish flu' virus

virus.

Then, they sent the bacteria containing the viral gene sequences to Tumpey, who inserted them into the cells to produce the virus.

The researchers also produced variations of the virus for comparison, with certain Spanish flu genes replaced by the corresponding genes from other flu viruses. Then they studied the viruses' effects in mice, chick embryos and human lung cells and identified the constellation of genes that was responsible for the Spanish flu virus' extreme virulence.

One gene associated with high virulence was the HA gene, which encodes the hemagglutinin surface protein that helps the virus attach to cells and replicate properly. This gene seemed to be responsible for much of the severe lung damage reported in people infected with the Spanish flu. The three genes encoding the viral "polymerase" enzymes, which form the virus' basic replication machinery, were also found to be important for high virulence.

"Given that HA is responsible for so much pathology in the lung, if we could identify the mechanism for how that happens and then block it, perhaps it would be useful for antiviral development. With the identification of the polymerase genes contributing to disease, that represents another set of genes that might also be a good target for prophylactic and therapeutic interventions," Tumpey said.

Although more research needs to be done on antivirals and vaccines for a future flu pandemic, Tumpey noted some encouraging signs. The FDA-approved flu antiviral drugs, oseltamivir and amantadine, have been shown to be effective against viruses carrying certain genes from the Spanish flu virus. And, vaccines containing the Spanish flu HA gene, as well as another gene from this virus, were protective in mice.


'"/>

Source:American Association for the Advancement of Science


Page: 1 2 3

Related biology news :

1. New possibilities to fight pests with biological means
2. Three-dimensional, miniature endoscope opens new diagnostic possibilities
3. Heart failure: Intervention possibilities from imaging programmed cell loss
4. The quest for an effective HIV vaccine presents new possibilities, challenges
5. Novel antiviral technology inhibits RSV infection in mice
6. Biota makes major antiviral discovery
7. The reason why antiviral therapy cant annihilate HIV infection, and what to do about it
8. Bird flu -- Call for antiviral drugs to be shared
9. Research advances quest for HIV-1 vaccine
10. A much-needed shot in the arm for HIV vaccine development
11. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
Post Your Comments:
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... technical, managerial and financial components of healthcare delivery to ... Disease) patient will be the topic of Stevens Institute ... October 31, 2007, from 3-5 p.m. in Room 122 ... Streets in Hoboken, NJ). , Roundtable participants will discuss ...
... a 46 percent increase in lifespan, raising the tantalizing ... are also taking an anti-aging medication. Results of the ... Lithgow, PhD, are currently published online in the Journal ... to treat mood affective disorders, including bipolar disease for ...
... daily commute may be taking more of a toll than ... of Southern California (USC) and the California Air Resources Board ... exposure to harmful air pollutants occurs while people are traveling ... spends about six percent (1.5 hours) of his or her ...
Cached Biology News:Stevens Health, Technology, and Society roundtable: Oct. 31 2Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms 2Time spent in car drives up air pollution exposure 2
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel ... National Eye Institute (NEI) at the National Institutes of ... grant to develop a drug-eluting intraocular lens (IOL) for ... of vision loss in people over age 40 and ... Ken Mandell, LayerBio’s Founder and CEO, "There is a ...
(Date:12/19/2014)... December 19, 2014 The empty ... the rising ageing population and technological innovations in ... nutraceutical industries are catalysing the growth of the ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , ... well as new entrants/smaller firms to gauge the ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 10, 2011 ... Lilly and Company (NYSE: LLY ) and ... positive results from a phase 2 study evaluating the ... on glycemic control in patients with type 2 diabetes. ...
... 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... a randomized pivotal trial of pixantrone for the treatment ... the  U.S. Food and Drug Administration,s (the "FDA") Division ... trial, referred to as the PIX-R or PIX 306 ...
... release is available in German . , From the ... to the strings and sound box of a guitar or violin, ... actual mechanical vibrations of these instruments create acoustic waves that we ... related to the decay of the vibration amplitude, that is, the ...
Cached Biology Technology:Exenatide Once Monthly Showed Positive Results in Phase 2 Study 2Exenatide Once Monthly Showed Positive Results in Phase 2 Study 3Exenatide Once Monthly Showed Positive Results in Phase 2 Study 4Exenatide Once Monthly Showed Positive Results in Phase 2 Study 5Exenatide Once Monthly Showed Positive Results in Phase 2 Study 6Exenatide Once Monthly Showed Positive Results in Phase 2 Study 7FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 2FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 3FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 4FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 5How long does a tuning fork ring? 2
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Adhesion Molecule Antibodies...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Biology Products: